Fei Lee

723 total citations
16 papers, 327 citations indexed

About

Fei Lee is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Biotechnology. According to data from OpenAlex, Fei Lee has authored 16 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Biotechnology. Recurrent topics in Fei Lee's work include CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Cancer Research and Treatments (3 papers). Fei Lee is often cited by papers focused on CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Cancer Research and Treatments (3 papers). Fei Lee collaborates with scholars based in United States, Germany and Netherlands. Fei Lee's co-authors include Jing Chen, Howard I. Scher, Francis M. Sirotnak, F. M. Sirotnak, Vincent A. Miller, Yuhong She, Jing Chen, Adriana Haimovitz‐Friedman, Valerie W. Rusch and Mark G. Kris and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Fei Lee

16 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fei Lee United States 8 135 130 108 72 56 16 327
Mary Luz Uribe Spain 8 153 1.1× 259 2.0× 104 1.0× 81 1.1× 35 0.6× 14 513
Hironori Kikkawa Japan 12 127 0.9× 226 1.7× 53 0.5× 55 0.8× 54 1.0× 23 418
Bruno Gomes Canada 10 171 1.3× 176 1.4× 78 0.7× 52 0.7× 71 1.3× 38 422
Ludimila Cavalcante United States 12 238 1.8× 148 1.1× 78 0.7× 60 0.8× 82 1.5× 54 423
François D’Anjou Canada 9 103 0.8× 227 1.7× 42 0.4× 71 1.0× 38 0.7× 12 352
Guo‐Liang Shen China 12 149 1.1× 206 1.6× 93 0.9× 89 1.2× 135 2.4× 48 464
Zhengkai Liao China 13 117 0.9× 235 1.8× 71 0.7× 72 1.0× 79 1.4× 31 429
Diane C. Wang China 11 97 0.7× 202 1.6× 107 1.0× 114 1.6× 64 1.1× 12 408
Ludmiła Grzybowska‐Szatkowska Poland 14 90 0.7× 215 1.7× 130 1.2× 77 1.1× 29 0.5× 42 466
J. Carmichael United Kingdom 10 243 1.8× 204 1.6× 84 0.8× 58 0.8× 26 0.5× 23 475

Countries citing papers authored by Fei Lee

Since Specialization
Citations

This map shows the geographic impact of Fei Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Lee more than expected).

Fields of papers citing papers by Fei Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Lee. The network helps show where Fei Lee may publish in the future.

Co-authorship network of co-authors of Fei Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Fei Lee. A scholar is included among the top collaborators of Fei Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei Lee. Fei Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Suurs, Frans V., Grit Lorenczewski, Julie M. Bailis, et al.. (2021). Mesothelin/CD3 Half-Life–Extended Bispecific T-Cell Engager Molecule Shows Specific Tumor Uptake and Distributes to Mesothelin and CD3-Expressing Tissues. Journal of Nuclear Medicine. 62(12). 1797–1804. 15 indexed citations
2.
Sternjak, Alexander, Fei Lee, Oliver S. Thomas, et al.. (2021). Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII. Molecular Cancer Therapeutics. 20(5). 925–933. 22 indexed citations
3.
Walker, Kenneth W., Ian N. Foltz, Tina Wang, et al.. (2020). The serum protein transthyretin as a platform for dimerization and tetramerization of antibodies and Fab fragments to enable target clustering. Journal of Biological Chemistry. 295(30). 10446–10455. 1 indexed citations
4.
Cooke, Keegan S., Juan Estrada, Jinghui Zhan, et al.. (2020). 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer. SHILAP Revista de lepidopterología. 1 indexed citations
5.
Jurcak, Noelle R., Fei Lee, Noah Rozich, et al.. (2019). Abstract 1561: Evaluation of mesothelin BiTE® antibody constructs in models of pancreatic ductal adenocarcinoma. Immunology. 1561–1561. 1 indexed citations
6.
Bailis, Julie M., Fei Lee, Michael J. Giffin, et al.. (2019). Abstract 553: Melanoma subtypes that emerge during adaptive resistance to therapy are targets for bispecific T cell engager (BiTE®) antibody constructs directed to CDH19 and DLL3. Cancer Research. 79(13_Supplement). 553–553. 2 indexed citations
7.
Jurcak, Noelle R., Fei Lee, Noah Rozich, et al.. (2019). Abstract 1561: Evaluation of mesothelin BiTE® antibody constructs in models of pancreatic ductal adenocarcinoma. Cancer Research. 79(13_Supplement). 1561–1561. 1 indexed citations
8.
Sternjak, Alexander, Fei Lee, Joachim Wahl, et al.. (2017). Abstract 3630: Preclinical evaluation of a BiTE® antibody construct with extended half-life that targets the tumor differentiation marker mesothelin. Cancer Research. 77(13_Supplement). 3630–3630. 1 indexed citations
9.
Li, Kexue, Lawrence R. McGee, Athena Sudom, et al.. (2013). Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure–activity relationship, and co-crystal structures. Bioorganic & Medicinal Chemistry Letters. 23(5). 1238–1244. 53 indexed citations
10.
Liu, Jinsong, Athena Sudom, Xiaoshan Min, et al.. (2012). Structure of the Nuclear Factor κB-inducing Kinase (NIK) Kinase Domain Reveals a Constitutively Active Conformation. Journal of Biological Chemistry. 287(33). 27326–27334. 42 indexed citations
11.
Sun, Baomin, et al.. (2010). Mathematical Analysis of O and OH Radicals Energized by Dielectric Barrier Discharge. 1–4. 1 indexed citations
12.
Desai, Varsha G., Taewon Lee, Robert R. Delongchamp, et al.. (2008). Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver. Mitochondrion. 8(2). 181–195. 25 indexed citations
13.
She, Yuhong, Fei Lee, Jing Chen, et al.. (2003). The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.. PubMed. 9(10 Pt 1). 3773–8. 54 indexed citations
14.
Sirotnak, Francis M., et al.. (2002). Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.. PubMed. 8(12). 3870–6. 81 indexed citations
15.
Brady, Mary S., Fei Lee, Howard T. Petrie, David D. Eckels, & Janet Lee. (2000). CD4 + T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro. Cancer Immunology Immunotherapy. 48(11). 621–626. 23 indexed citations
16.
Brady, Mary S., et al.. (2000). Restoration of Alloreactivity of Melanoma by Transduction With B7.1. Journal of Immunotherapy. 23(3). 353–361. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary Luz Uribe Breakdown of academic impact, for papers by Hironori Kikkawa Breakdown of academic impact, for papers by Bruno Gomes Breakdown of academic impact, for papers by Ludimila Cavalcante Breakdown of academic impact, for papers by François D’Anjou Breakdown of academic impact, for papers by Guo‐Liang Shen Breakdown of academic impact, for papers by Zhengkai Liao Breakdown of academic impact, for papers by Diane C. Wang Breakdown of academic impact, for papers by Ludmiła Grzybowska‐Szatkowska Breakdown of academic impact, for papers by J. Carmichael
Rankless by CCL
2026